Kleanthis G. Xanthopoulos, Ph.D., was most recently the President & Chief Executive Officer of Regulus Therapeutics, LLC. since December 2007. Before joining Regulus, shortly after its formation, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. Prior to that, he was a co-founder and served as President and Chief Executive Officer and Director of Anadys Pharmaceuticals (NASDAQ:ANDS) from its inception in May 2000 to November 2006. From 1997 to 2000 he was an executive at Aurora Biosciences Corporation (now Vertex Pharmaceuticals Incorporated) as Vice President. Dr. Xanthopoulos participated in The National Institutes of Health Human Genome Project and was a Section Head of the National Human Genome Research Institute from 1995 to 1997. He was an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Stockholm, Sweden from 1991 to 1995, and a Postdoctoral Research Fellow at The Rockefeller University from 1987 to 1990. An Onassis scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of Anadys Pharmaceuticals, Odyssey Thera, Inc., and an executive board member of BIOCOM, Southern California's life science industry association, where he chairs the Capital Formation Committee.
Over the past year, we’ve witnessed the biotech bull market expand, deflate and expand again—specifically in relation to RNA-based therapeutic companies. The innovators in the space have increased and decreased their... Read more »
RNA therapeutics are new, innovative high-impact medicines. The combined efforts of pioneering biotechnology companies, pharmaceutical and academic institutions have helped these treatments, which act on ribonucleic acids in the cell, to... Read more »